Case Reports:

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case report and review of the literature

Zhiyao Bao, Hong Chen, Min Zhou _, Guochao Shi, Qingyun Li and Huanying Wan

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:38069-38074. https://doi.org/10.18632/oncotarget.16971

Metrics: PDF 2260 views  |   HTML 4532 views  |   ?  


Zhiyao Bao1,*, Hong Chen1,*, Min Zhou1, Guochao Shi1, Qingyun Li1 and Huanying Wan1

1 Department of Respiratory Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Min Zhou, email:

Keywords: invasive pulmonary aspergillosis, COPD, Aspergillus fumigatus

Received: December 20, 2016 Accepted: March 13, 2017 Published: April 08, 2017


Invasive pulmonary aspergillosis (IPA) is an infection that often occurs in immunocompromised patients and has a high mortality rate. In recent years, the reported incidence of IPA in the context of chronic obstructive pulmonary disease (COPD) has seemingly increased. The combination of factors such as long-term corticosteroid use, increasing rate of bacterial exacerbations over time, lung immune imbalance, and malnutrition are responsible for the emergence of IPA in COPD patients. A diagnosis of IPA in COPD patients is difficult to make, which explains the delay in antifungal therapy and the high mortality rate. The purpose of this study is to increase the recognition and improve the outcomes associated with this situation through the description of our case. In patients in which IPA is suspected, comprehensive analysis of their clinical manifestations, imaging, microbiology and serological examination results are effective means of increasing the rate of reliable diagnosis. If the patient’s condition permits, a pathological specimen should be obtained as soon as possible.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16971